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Abstract
Background
Recurrent strokes occur in 25% of the cases during the first 5 years after the initial event. Each recur-
rent stroke increases the risk for severe disability and mortality. Intravenous thrombolysis (IVT) with 
recombinant tissue plasminogen activator (rtPA) is one of the therapeutic options when secondary 
prevention is not efficient and recurrent stroke occurs.
Aim
Aim of this paper is to present the first ever case of repeated IVT with rtPA in a female patient with 
recurrent stroke, hospitalized at the Department for Urgent Neurology, University Clinic of Neurology 
in Skopje, North Macedonia with a review from the literature.
Case presentation
A 59 years old female patient was admitted due to acute onset of motor and sensory dysphasia and 
right-sided hemiplegia. The symptoms occurred 1,5 hours before admission. Urgent computed 
tomography (CT) of the brain showed chronic cerebral infarction in the left and parietal regions, 
which causing traction of the left lateral ventricle. The patient experienced her first ischemic stroke 2,5 
years ago and she was treated with IVT at the time. At the second hospital admission, the patient was 
conscious, with vital signs and urgent laboratory parameters within normal range. NIHSS score was 13 
and a decision for IVT treatment was made. During the application of rtPA, her vital parameters were 
stable and no side effects were observed. Neurological status of the patient also improved, with NIHSS 
of 7 at the end of the IVT treatment. Control CT scan performed 24 hours after was without any new 
lesions. The patient was discharged in a stable condition, with a NIHSS of 4 and mRS of 3. 
Conclusion
Repeated IVT in recurrent stroke is feasible and safe in carefully selected patients. Assessment of risk 
factors and neuroimaging are crucial when deciding on repeated IVT. 
Keywords: recurrent stroke, repeated intravenous thrombolysis, recombinant tissue plasminogen 
activator
Sažetak
Ponovljena intravenska tromboliza kod bolesnika s recidivom ishemijskog moždanog udara – 
prikaz slučaja i prikaz iz literature
Uvod
Recidivi moždanih udara javljaju se u 25% slučajeva tijekom prvih 5 godina nakon inicijalnog 
događaja. Svaki ponovljeni moždani udar povećava rizik za težu onesposobljenost i smrtnost. Intra-
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Introduction
Acute ischemic stroke (AIS) is caused by thrombotic or embolic 
occlusion of a cerebral artery, resulting in a corresponding loss/
deterioration of neurologic functions. According to the World 
Health Organization (WHO), 15 million people in the world 
suffer from stroke each year. Of them, 5 million have lethal 
outcome, and another 5 million are left permanently disabled 1. 
Men have higher risk for stroke than women, with an incidence 
of 62.8 per 100,000, and a mortality rate of 26.3%. Women 
have a stroke incidence of 59 per 100,000 and a mortality rate of 
39.2%. Risk of stroke increases with age, and 75% of all strokes 
occur in patients older than 64 years. 
According to the guidelines from the European Stroke Organi-
zation (ESO) and the American Heart and Stroke Association 
(AHA/ASA), intravenous thrombolysis (IVT) with recombinant 
tissue-type plasminogen activator (rtPA) is included therapy for 
acute ischemic stroke in selected patients, in a time window of 
3-4,5 hours after symptom onset is 2,3.
The treatment after IVT consists of optimal strategy for second-
ary stroke prevention. However, recurrent strokes occur in 25% 
of the cases during the first 5 years after the initial event. Each 
recurrent stroke increases the risk for severe disability and mor-
tality 4. IVT is one of the therapeutic options when secondary 
prevention is not efficient and recurrent stroke occurs. However, 
the application raises certain concerns regarding its short-term 
venska tromboliza (IVT) s rekombinantnim tkivnim aktivatorom plazminogena (rtPA) jedna je od 
terapijskih mogućnosti u slučajevima kada sekundarna prevencija moždanog udara nije učinkovita te 
nastupi recidiv moždanog udara.
Prikaz slučaja
Predstavljamo prvi slučaj na našoj klinici s recidivom moždanim udarom liječenim ponovljenim IVT. 
59-godišnja pacijentica primljena je zbog akutne pojave senzomotore disfazije i desne hemiplegije. 
Simptomi su se javili 1,5 sata prije prijema u bolnicu. Hitna kompjuterizirana tomografija (CT) mozga 
nije pokazala nove lezije, dok su se prikazale malacijske lezije u lijevoj frontalnoj i parijetalnoj regiji 
uzrokujući retraktilne promjene na  lijevu lateralnu moždanu klijetku. Pacijentica je prvi ishemijski 
moždani udar doživjela prije 2,5 godine i tada je liječena IVT-om. Pri ovom prijemu u bolnicu, paci-
jentica je bila pri svijesti, s vitalnim znakovima i hitnim laboratorijskim parametrima unutar normal-
nih granica. NIHSS rezultat je bio 13 i donesena je odluka o IVT liječenju. Tijekom primjene rtPA, 
vitalni su joj parametri bili stabilni i nisu primijećene nuspojave. Neurološki status pacijenta također se 
poboljšao na NIHSS od 7 na kraju IVT-a. Kontrolno CT snimnanje mozga nakon 24 sata nije poka-
zalo novih lezija. Pacijentica je otpušten u stabilnom stanju, s NIHSS 4 i mRS 3.
Zaključak
Ponovljeni IVT kod ponovljenog moždanog udara izvediv je i siguran kod pažljivo odabranih bole-
snika. Procjena čimbenika rizika i nalaz neuoslikovnih metoda prikaza mozga presudni su pri odluci o 
ponovljenoj primjeni IVT-a.
Ključne riječi: recidivirajući moždani udar; ponovljena tromboliza; rekombinantni tkivni aktiva-
tor plazminogena. 
and long-term side effects. Complications of intravenous rt-PA 
for acute ischemic stroke are commonly related to hemorrhage, 
arterial reocclusion, anaphylaxis, or reperfusion damage.
Aim of this paper is to present the first ever case of repeated IVT 
with rtPA in a female patient with recurrent stroke, hospitalized at 
the Department for Urgent Neurology, University Clinic of Neurol-
ogy in Skopje, North Macedonia with a review from the literature.
Case presentation
We present a case of a 59 years old female patient, who was 
admitted at the Department for Urgent Neurology, University 
Clinic of Neurology, due to acute onset of motor and sensory 
dysphasia and right-sided hemiplegia (facio-brachial type). The 
symptoms occurred 1,5 hours before admission. Beside well con-
trolled hypertension, the patient did not have any vascular risk 
factors. Urgent computed tomography (CT) of the brain showed 
chronic cerebral infarction in the left and parietal regions, which 
causing traction of the left lateral ventricle. (Figure 1). 
In fact, the patient experienced her first ischemic stroke 2,5 years 
ago and she was treated with IVT at the time. After the first 
hospitalization, the patient was dismissed with dual antiplatelet 
therapy (ASA and clopidogrel), statin (rosuvastatin) and antihy-
pertensive therapy. After 3 weeks, clopidogrel was stopped and 
the patient continued monotherapy with ASA. In the follow-
ing period after the first stroke, the patient recovered almost 
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completely, with residual right sided hemiparesis of mild degree 
(with National Institute of Health Stroke Scale (NIHSS) of 4 
and modified Rankin Score (mRS) of 2). 
At the second hospital admission, the patient was conscious, with 
vital signs (blood pressure 125/75 mmHg; heart rate- rhythmic, 
frequency 66/minute) and urgent laboratory parameters (glyce-
mia 5,7 mmol/L, platelets 283 10˄ 9/L) within normal range. 
NIHSS score was 13 and therefore, a decision for IVT treatment 
was made, taken into consideration that the patient fulfilled 
the inclusion criteria. With a door-to-needle (DTN) time of 60 
minutes, Actilyse was given according the protocol, in a thera-
peutical dose of 63 ml. During the application of Actilyse, her 
vital parameters were stable and no side effects were observed. 
Neurological status of the patient also improved, with NIHSS of 
7 at the end of the IVT treatment. 
Control CT scan performed 24 hours after was without any new 
lesions (Figure 2). Other laboratory results (blood and urine 
analysis, D-dimers and coagulation factors) obtained during the 
hospitalization were in normal range. Color duplex sonography 
of the extracranial carotid and vertebral arteries was normal. The 
next day after IVT treatment, antiplatelet (ASA), prophylactic 
anticoagulation (LMWH) and statin (atorvastatin) therapy was 
initiated, as well as antihypertensive (lisinopril), anxiolytic (diaz-
epam) and physical therapy. 
Her neurological status furtherly improved and after 13 days 
of hospitalization the patient was dismissed in a stable condi-
tion, with a NIHSS of 4 and mRS of 3. We recommended dual 
antiplatelet therapy (combination of clopidogrel and cilostazol 
for the duration of 3 weeks, and than only clopidogrel), statin 
(rosuvastatin) and antihypertensive therapy (ACE inhibitor). We 
did not recommend ASA because the patient experienced recur-
rent stroke despite regular previous treatment with this medica-
tion. On follow-up control examinations in the next 3 months, 
the patient was stable with only mild residual neurologic deficit. 
  
  
Figure 1. First CT scan with large postapoplectic sequela in the left frontal and parietal region 
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Discussion
This patient was the first ever case at our clinic with recurrent 
stroke treated with repeated IVT. In the period 2015-2020 there 
was a total of 170 patients treated with IVT at the clinic, an 
average of 9% out of the total number of stroke patients.
Data from the literature show limited experience regarding 
repeated thrombolytic treatments in stroke patients. This pro-
cedure can be considered in a stroke patient if the initial IVT 
attempt has been unsuccessful or if the recurrent stroke has oc-
curred 3 months after the first event 2,5. 
The following papers have described repeated IVT use in recur-
rent stroke occurring more than 3 months after the initial event.
Arsava and Topcioglu described de-novo thrombolysis for recur-
rent stroke in a patient with prior history of thrombolysis 6. A 
67-year-old male with prior history of atrial fibrillation was 
admitted with acute onset of aphasia and he was treated by IVT. 
Approximately 2 years later he presented with left-sided weak-
ness, and was again treated with intravenous rtPA. The patient 
responded favorably to thrombolytics on both occasions, without 
significant complications and with satisfactory recovery. Their 
study, although reflecting experience from a single case, high-
lights that repeated administration of intravenous rtPA is well 
tolerated in stroke patients with late recurrences and previous 
history of thrombolysis. 
Yoo et al. investigated patients with acute ischemic stroke who had 
received thrombolytic treatments for a period of 10 years 7. Of the 
437 patients who received thrombolytic treatments, only 7 under-
went repeated thrombolysis (1.6%). The median age at the time of 
repeated thrombolytic therapy was 71 years old; 4 of the patients 
were female. All patients had 1 or more potential sources of cardiac 
embolism. Recanalization was achieved in all patients, in both the 
first and the second thrombolysis. No symptomatic ICH occurred 
after repeated thrombolytic treatments. Five patients (71.4%) 
showed good outcomes at 3 months. The authors concluded that 
   
  
Figure 2. Control CT of the brain that did not show any new lesions, only large postapoplectic sequela in the left frontal and parietal region 
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among patients who experience recurrent acute ischemic stroke, 
thrombolytic therapy could be considered even if the patient has 
had previous thrombolytic treatments.
Cappellari et al. described 8 patients with repeated IVT after re-
current stroke among 615 consecutive stroke patients who received 
IVT at their Stroke Unit and 22 cases of IV re-thrombolysed 
patients extracted for the literature review of case reports and case 
series 8. After excluding the 6 patients treated with endovascular 
procedures, they included in the analyses 21 patients for which 
they had data on pre-stroke functional status and baseline neuro-
logical severity for each stroke event and post-treatment functional 
status for each IVT. They compared second (n = 21) and third 
(n = 3) IVT treatments with first IVT treatments (n = 21). Also, 
they compared IVT re-treatments ≤3 months from previous IVT 
thrombolysis (n = 10) with those N3 months (n = 14). No signifi-
cant differences in the rate of ICH with neurological deterioration, 
mortality and restitution of the pre-existing functional status were 
observed in the comparative analyses. The authors emphasized that 
repeated IVT may be safe and effective when recurrent stroke oc-
curs after a period of complete neurologic regression lasting at least 
24 h or minor disability (mRS score ≤2) lasting at least 3 months 
since the previous stroke.
Papers that described use of repeated IVT in patients with early 
recurrent stroke have also been published. 
Ashrafi et al. described a case report with a secondary stroke after 
thrombolytic administration 9. The patient was a 68-year-old 
man with the history of uncontrolled hypertension and diabetes 
mellitus presented with acute ischemic stroke in the territory of 
vertebrobasilar system to the emergency department. Atrial fibril-
lation (AF) rhythm, hyperglycemia and uncontrolled hyperten-
sion were recorded on admission. Echocardiography performed 
before thrombolysis, did not identify any embolic sources. Five 
hours after intravenous injection of rtPA, the patient became 
comatose and developed a recurrent infarction in the territory of 
right middle cerebral artery (MCA). The authors concluded that 
thrombolysis therapy in patients with the risk factors of recur-
rent stroke, must be done with more preparation and readiness 
for concurrent processing. Regardless of normal trans-thoracic 
echocardiography, in patients with AF rhythm, transesophageal 
echocardiography may be helpful. 
Wu et al. conducted a systemic literature review in PubMed up 
to December, 2015 10. A total of 15 studies involving 57 cases 
and 61 randomized trials (RTs) were collected. The median age 
of the patients was 73 at the first event, the median time interval 
was 225 days and 45.9% were female. High severity and worse 
functional outcome were observed in the RT group, but the 
difference of ICHs from 2 events did not reach statistical sig-
nificance. More ICHs occurred in RTs with prior stroke within 
last 30 days than those in chronic stroke phase in a subgroup 
analysis (25.0–4.9%, p = 0.018). Only NIHSS was significantly 
associated with a good functional outcome (OR 0.921, 95% 
CI 0.857–0.990) and ICH (OR 1.177, 95% CI 1.031–1.344) 
in the logistic regression analysis. Their literature review indi-
cated that baseline stroke severity was the main predictor of the 
functional outcome and ICH after RT, similar to the results of 
the first thrombolysis in AIS. The accumulation of disability 
(measured by NIHSS) in recurrent stroke could have contributed 
to the worse prognosis after RT. 
Kahles et al. reported the largest case series of repeated IVT 
in early recurrent stroke (ERS) 11. They identified 19 subjects 
with repeated IVT in ERS. Mean age was 68±12 years, and 
37% of them were female. Median interthrombolysis interval 
was 30 days (interquartile range, 13–50). Functional independ-
ence (modified Rankin scale score ≤2) was achieved in 79% of 
patients after the first and in 47.4% after repeated IV tissue-type 
plasminogen activator, respectively. There was no symptomatic 
ICH. Median final infarct volume after the first IVT was 1.5 
cm3 (interquartile range, 0.5–3.1). The authors concluded that 
patients with small infarct volumes and robust clinical improve-
ment might be considered for repeated IVT within 3 months. 
Caruso et al described a case report with early repeated throm-
bolysis 12. They presented a 59-year-old man with stroke and 
NIHSS of 16, 10 days after a previous stroke. Brain computed 
tomography (CT) showed a previous hypodensity with 4 cm3 
volume. Angio-CT highlighted the left middle cerebral artery 
and left internal carotid occlusion. Perfusion CT showed small 
deep core and large penumbra. The patient underwent intra-
venous rtPA. After 24 hours, the NIHSS was 7, and CT scan 
showed an acute ischemic lesion in the left basal ganglia area and 
frontal lobe without hemorrhagic transformation. The authors 
concluded that this case report suggests that further randomized 
studies may evaluate whether repeated intravenous rtPA may be 
safe and effective in ERS occurring shortly after a previous stroke 
when patients experience a period of complete neurological 
regression, minor disability, and a small infarct volume. 
Sarmiento et al. described the safety and efficacy of repeated 
thrombolysis with alteplase in early recurrent ischemic stroke in 
a systematic review 13. They included ten articles with 33 patients 
in total. One patient developed symptomatic ICH after the 
second reperfusion attempt and subsequently died from pneu-
monia. Another died from spontaneous rupture of previously 
unidentified infrarenal aortic aneurysm. Six of the 13 patients 
with available follow-up data had good clinical outcomes (mRS 
0-2). There were no allergic reactions and other drug-related 
adverse events noted. The authors concluded that repeated IV 
alteplase can be safe and efficacious in patients who have early 
recurrent ischemic stroke. 
Regarding the early post-IVT treatment of our patients, we 
recommended dual antiplatelet therapy which included clopi-
dogrel and cilostazol. The combination of cilostazol with ASA 
or clopidogrel showed a reduced incidence of ischaemic stroke 
recurrence and a similar risk of severe or life-threatening bleed-
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ing compared with treatment with ASA or clopidogrel alone in 
patients at high risk for recurrent ischaemic stroke 14. Although 
majority of the clinical trials have been performed in Asian 
population 15, we speculated that the patient had a clinical resist-
ance to ASA and recommended cilostazol instead. 
We also recommended anxiolytic therapy with diazepam, which 
has been shown to have benefit in cardioembolic infarct patients 
and is safe in acute ischemic stroke 16.
The strengths of our case report are: 
1. This is the first ever successful application of repeated IVT 
in a recurrent stroke at our clinic. The decision was not easy, 
taken into account the large chronic ischemic lesion on the 
CT scan. 
2. The combination of dual antiplatelet therapy with clopi-
dogrel and cilostazol, although unusual for Caucasian popu-
lation has shown efficacy and safety in our patient.
The limitation of our case report are:
1. We could not define the exact cause of the recurrent stroke, 
but speculated that it occurred due to clinical resistance to 
ASA.
Conclusion
Our case report case report satisfies current trends in treatment 
of recurrent stroke. Repeated IVT in recurrent stroke is feasible 
and safe in carefully selected patients. Assessment of risk factors 
and neuroimaging scans is crucial when deciding on repeated 
IVT. There is a need for larger studies, defined inclusion and 
exclusion criteria and updated protocol in order to minimize 
side-effects of the repeated IVT in recurrent stroke patients.
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